Core Viewpoint - EnWave Corporation has announced a private placement agreement to sell up to 7,500,000 common shares at C$0.40 per share, aiming for gross proceeds of up to C$3,000,000, with a minimum of C$2,000,000 required to proceed with the offering [1][4] Group 1: Offering Details - The offering will be conducted under the Listed Issuer Financing Exemption, allowing shares to be sold without a hold period under Canadian securities laws [2] - The expected closing date for the offering is around August 21, 2025, pending necessary approvals [4] - Clarus Securities Inc. will receive a cash commission of 5.5% of the gross proceeds and non-transferable compensation options equal to 5.5% of the shares sold [5] Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to the construction of two large-scale Radiant Energy Vacuum (REV™) dehydration machines, which will take approximately six months to manufacture [3] Group 3: Company Overview - EnWave is a leader in vacuum microwave dehydration technology, with a strong intellectual property portfolio and a focus on food, pharmaceutical, and cannabis industries [7] - The company has over fifty partners across twenty-four countries, utilizing its technology to create innovative products and improve existing offerings [8] - EnWave's strategy includes signing royalty-bearing commercial licenses with food producers to enhance drying efficiency compared to traditional methods [9]

Core Viewpoint - NewLake Capital Partners reported solid second-quarter results for 2025, with revenue and net income exceeding analyst expectations, reflecting stability in a challenging cannabis industry environment [1][5][14] Financial Performance - GAAP revenue for Q2 2025 was $12.9 million, surpassing estimates of $12.49 million, and showing a year-over-year increase of approximately 3.8% [1][2] - Adjusted funds from operations (AFFO) per share reached $0.55, up from $0.53 in Q2 2024, indicating a 3.8% increase [2] - Net income attributable to common stockholders rose to $7.3 million, a 7.4% increase from $6.8 million in Q2 2024 [2] - The quarterly dividend remained stable at $0.43 per share, aligning with the company's 80–90% AFFO payout ratio policy [14] Business Overview - NewLake Capital Partners focuses on acquiring and leasing commercial real estate to companies in the regulated U.S. cannabis sector, with a portfolio of 34 properties [3] - The business model relies on long-term sale-leaseback agreements, providing financing to cannabis businesses in exchange for predictable rental income [3] Operational Focus - The company is concentrating on managing tenant credit risk, growing its property portfolio, and maintaining strong REIT compliance [4] - Recent quarters have seen a focus on portfolio stability, limiting new acquisitions due to industry headwinds and pauses in capital expenditure by cannabis companies [4] Tenant Risk and Industry Conditions - Tenant credit quality is a significant concern, with Revolutionary Clinics entering receivership and affecting rental income [10] - AYR Wellness, contributing approximately 5.9% of rental revenue, is undergoing restructuring, creating uncertainty around future rental income [11] - The overall tenant portfolio remains stable, but financial health is a sector-wide risk [12] - Industry conditions for new investments are subdued, with reduced deal activity and a decline in the need for sale-leaseback financing [13] Liquidity and Balance Sheet - As of June 30, 2025, NewLake held $21.9 million in cash and cash equivalents, with total liquidity of $104.3 million [7] - The company has minimal debt, with only $7.6 million drawn on its revolving credit line and no debt maturities until May 2027 [7] Future Outlook - No formal financial guidance was provided for future quarters, making the outlook dependent on property-level performance and tenant challenges [15] - Management emphasized the need to monitor tenant credit events, acquisition opportunities, and regulatory trends in the sector [15]

Core Insights - MariMed Inc. reported financial results for Q2 2025, highlighting growth in operations and revenue, driven by its "Expand the Brand" strategy [1][2] - The company anticipates further growth through new market entries and expanded product distribution [2] Financial Performance - Q2 2025 revenue was $39.6 million, a slight decrease from $40.4 million in Q2 2024 [3] - GAAP gross margin for Q2 2025 was 40%, down from 42% in Q2 2024, while non-GAAP gross margin remained stable at 42% [3] - The company reported a GAAP net loss of $1.3 million for Q2 2025, compared to a loss of $1.6 million in Q2 2024 [3] - Non-GAAP adjusted EBITDA for Q2 2025 was $4.9 million, an increase from $4.4 million in Q2 2024, with an adjusted EBITDA margin of 12% [3] Operational Highlights - The company expanded its product offerings and market presence, including the launch of new products and entry into Pennsylvania [5][9] - MariMed's retail and wholesale revenues showed sequential growth, reflecting strong execution in key markets [2][5] Strategic Initiatives - The management emphasized the importance of brand leverage as a growth engine and highlighted plans for adult-use sales in Delaware and a new licensing agreement in Maine [2][5] - The company is exploring M&A and licensing opportunities, supported by a strong balance sheet [2][5] Cash Flow and Balance Sheet - Cash and cash equivalents at the end of Q2 2025 were $6.1 million, down from $7.3 million at the end of 2024 [19][22] - Total assets decreased to $204.4 million from $207.0 million at the end of 2024, while total liabilities increased to $131.2 million [19][20]

Financial Performance - Total revenue for Q2 2025 was $315 million, representing a 1.5% increase compared to Q1 2025 [2] - Adjusted gross margin for Q2 2025 was 49%, an increase of 120 basis points year-over-year [2][7] - Adjusted EBITDA for Q2 2025 was $66 million, resulting in a 21% adjusted EBITDA margin [2][24] - Net loss from continuing operations for Q2 2025 was $50.6 million, or $0.07 per share [7][30] International Expansion - Curaleaf was awarded a license to operate in Turkey's medical cannabis market, expanding its international footprint [2][7] - The international segment reported a 62% year-over-year growth, with international revenue of $41 million in Q2 2025 [2][8] Operational Highlights - The company ended Q2 2025 with $102 million in cash after making $47 million in interest and debt payments [2][9] - Curaleaf opened its 66th retail location in Florida and launched new product lines, including a new pre-roll brand and an ultra-clear oil [7][8] - The company completed the buyout of its minority partner in Curaleaf International, now owning 100% of the business [7] Market Position and Strategy - Curaleaf operates in 17 U.S. states and 15 countries, positioning itself as a global cannabis leader [2] - The company is focusing on product quality, customer service, and supply chain excellence to capitalize on emerging opportunities in the cannabis market [2]

Core Insights - Aurora Cannabis reported a first-quarter fiscal 2026 loss per share of 26 cents, missing the Zacks Consensus Estimate of 18 cents per share and reversing a profit from the prior year [1][7] - The company's total net revenues reached $98 million, reflecting a year-over-year increase of 17.5% and surpassing the Zacks Consensus Estimate by 38.3% [3][7] Revenue Performance - The revenue growth was primarily driven by strong international medical cannabis sales, particularly in Australia, Germany, Poland, and the UK, alongside increased revenues in Canada [4][8] - The Global Medical Cannabis segment generated $64.8 million in revenues, up 37% year over year, making it the strongest contributor to the company's revenue [5][8] - International Medical Cannabis revenues surged 84.7% year over year to $37.1 million, while Canadian Medical Cannabis revenues increased by 2.1% to $27.7 million [8][9] Segment Analysis - Consumer cannabis revenue declined by 32% year over year to $7.9 million, as the company prioritized high-margin medical cannabis over the lower-margin consumer segment [9] - The Plant Propagation segment, primarily from the Bevo business, contributed $23.9 million, up 3.8% from the previous year [10] Financial Metrics - Gross profit decreased by 34.9% year over year to $27.9 million, but the adjusted gross margin improved by 1000 basis points to 52% [11] - Total operating expenses rose by 9.7% year over year to $48.2 million, with significant increases in general and administration expenses [11][12] Financial Position - At the end of the first quarter, Aurora Cannabis had cash and cash equivalents of $140.2 million, slightly up from $137.9 million at the end of fiscal 2025 [13] - Net cash provided by operating activities increased to $10.1 million compared to $8.3 million a year ago [13] Future Guidance - The company anticipates consolidated net revenue growth in the fiscal second quarter of 2026, with Global Medical Cannabis revenue expected to increase by 8%-12% [14] - The Plant Propagation segment is expected to align with traditional seasonal trends, with a significant portion of annual revenue typically earned in the second half of the calendar year [14][15]

Why One-Time Cannabis Darling Tilray Is Now High On Beer https://t.co/1rPyj01O5P https://t.co/1rPyj01O5P ...

Financial Data and Key Metrics Changes - Net revenue increased by 17% to $98 million, with global medical cannabis revenue rising by 37% and international revenue growing by 85% [6][18] - Adjusted gross margin improved by 1,000 basis points to 52%, benefiting from higher cannabis margins [6][17] - Adjusted EBITDA more than doubled to $11 million, with positive free cash flow of $9 million [7][22] Business Line Data and Key Metrics Changes - Medical cannabis net revenue rose by 37% to $64.8 million, comprising 66% of total net revenue [18][19] - Consumer cannabis net revenue decreased to $7.9 million, down from $11.5 million, as the focus shifted to higher-margin medical cannabis [19] - Plant propagation net revenue increased by 4% to $23.9 million, marking a record quarter for the company [20] Market Data and Key Metrics Changes - Aurora holds a leading market position in Canada, Australia, Germany, Poland, and the UK, with significant growth opportunities in these regions [7][10] - The Australian market is growing rapidly, with Aurora holding the number two market share [10] - In Germany, the descheduling in April 2024 has led to increased patient registrations and higher prescription volumes [12] Company Strategy and Development Direction - The company aims to capitalize on the global medical cannabis market, projected to exceed $5 billion, particularly in Europe and Australia [26] - Aurora has built strong competitive barriers through scientific expertise and regulatory navigation, focusing on premium product offerings [26] - The company is investing in new cultivation technology and establishing third-party partnerships to optimize production [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating potential regulatory changes in Germany, emphasizing the company's preparedness [12][52] - The company anticipates continued strong performance in Q2, with expected year-over-year revenue growth driven by the global medical cannabis segment [23][47] - Management highlighted the importance of maintaining high-quality products to succeed in competitive markets [57] Other Important Information - The company ended the quarter with $186 million in cash and cash equivalents, with no debt in its cannabis operations [22] - Adjusted SG&A expenses increased by 19% to $37.4 million, reflecting higher selling and distribution costs [21] Q&A Session Summary Question: Higher SG&A expenses and future expectations - Management explained that SG&A expenses are variable costs tied to revenue growth, with some one-time costs related to the integration of Med Relief Australia [31][33] Question: Competition in Europe and margin structure - Management acknowledged increased competition in Europe but emphasized Aurora's established market position and ability to navigate regulatory challenges [35][36] Question: Vivo liabilities and audit process - Management clarified that the movement of Vivo's liabilities to current is an accounting treatment and does not impact the audit process [43][45] Question: Q2 guidance on adjusted EBITDA - Management expects positive adjusted EBITDA in Q2, with growth compared to Q1 [47] Question: Regulatory changes in Germany - Management indicated that potential regulatory changes in Germany would likely be clearer by the end of the year, with a focus on maintaining a strong market position [51][52] Question: Market conditions in Poland - Management confirmed that demand and sales in Poland have returned to previous levels, with a focus on high-quality products [57][58] Question: Supply chain and third-party purchases - Management stated that 90% of production is GMP certified, with ongoing investments in facilities to increase yield and potency [63][64] Question: Opportunities for vertical integration - Management discussed the potential for downstream integration and partnerships with clinics and distributors, emphasizing the importance of product quality [68][70]

Core Insights - Glass House Brands Inc. is set to report its financial results for Q2 2025 on August 13, 2025, after market close [1] - A conference call will be held at 5:00 p.m. Eastern Time to discuss the results [1] Company Overview - Glass House Brands is recognized as one of the fastest-growing, vertically integrated cannabis companies in the U.S., focusing primarily on the California market [3] - The company aims to build leading brands across all consumer segments, with a portfolio that includes Glass House Farms, PLUS Products, Allswell, and Mama Sue Wellness [3] - Glass House operates a network of retail dispensaries in California, including The Farmacy, Natural Healing Center, and The Pottery [3] - The company's vision emphasizes producing outstanding cannabis products sustainably for the benefit of all [3]

Core Viewpoint - FLUENT Corp. announces the resignation of CEO Robert Beasley, effective August 8, 2025, as part of a mutual decision to facilitate a leadership change for the company's strategic priorities [1][2]. Company Overview - FLUENT is a national cannabis consumer packaged goods company and retailer, committed to operational excellence in cultivation, production, distribution, and retail experience [3]. - The company operates in Florida, New York, Pennsylvania, and Texas, employing over 700 staff across 8 cultivation and manufacturing facilities and 42 active retail locations [3]. - FLUENT produces a diverse portfolio of cannabis products under brands such as MOODS, Knack, Wandr, Bag-O, and Hyer Kind [3]. Leadership Transition - William Smith, Executive Chair of the Board, expressed gratitude for Robert Beasley's leadership and contributions, emphasizing the company's readiness for future growth [2]. - David Vautrin, former Chief Commercial Officer, will serve as Interim Chief Executive Officer starting August 8, 2025, while the search for a permanent CEO begins [2].

Core Insights - Aurora Cannabis Inc. reported a strong first quarter for fiscal 2026, with a 37% increase in global medical cannabis net revenue, driven by significant growth in international markets, particularly Germany and Poland [2][5][7] - The company achieved over 200% growth in adjusted EBITDA and a 42% increase in positive free cash flow, indicating robust operational performance [2][8][16] - The international medical cannabis segment now represents 57% of total net revenue, highlighting the company's competitive advantage in this high-margin area [3][7] Financial Performance - Total net revenue for Q1 2026 was $98.0 million, up 17% from $83.4 million in the prior year, primarily due to the growth in medical cannabis and plant propagation businesses [5][21] - Adjusted gross margin before fair value adjustments improved to 52% in Q1 2026 from 42% in the prior year, with adjusted gross profit increasing by 42% to $49.0 million [6][21] - Medical cannabis net revenue reached $64.8 million, a 37% increase year-over-year, contributing 66% of total consolidated net revenue [7][21] Segment Performance - International medical cannabis revenue surged by 85% to $37.1 million, driven by increased sales in Australia, Germany, Poland, and the UK [8][21] - Consumer cannabis net revenue decreased by 32% to $7.9 million, as the company prioritized high-margin medical cannabis products over lower-margin consumer offerings [10][21] - Plant propagation revenue from Bevo Farms increased by 4% to $23.9 million, supported by organic growth and expanded product offerings [12][21] Operational Efficiency - Adjusted SG&A expenses rose to $37.4 million, reflecting higher logistics costs associated with European sales and the acquisition of MedReleaf Australia [14][21] - The company maintained a strong balance sheet with approximately $186.0 million in cash and a debt-free cannabis business, with only non-recourse debt of $59.8 million related to Bevo Farms [4][21] Future Outlook - For Q2 2026, the company anticipates continued revenue growth, primarily driven by an 8% to 12% increase in the global medical cannabis segment [17][21] - Consolidated adjusted gross margins are expected to improve, with positive adjusted EBITDA projected to continue [18][21] - Free cash flow is expected to remain positive on an annual basis, despite anticipated cash outflows in Q2 2026 [19][21]